Sign in to view source links and access this dataset
Description
1,403 FDA-approved compounds were screened using two complementary hepatocyte reporter models to identify modulators of hepatitis B virus covalently closed circular DNA. The dataset contains results from a replication-competent HBV reporter in HepaRG cells and a Cre/Lox-based recombinant cccDNA reporter in HepG2 cells, which produced a luminescent readout aligned with cccDNA activity. This dual-reporter strategy identified 13 concordant, non-cytotoxic hits, such as palovarotene, for streamlining early-stage HBV drug discovery.
Use Cases
Prioritizing candidate cccDNA transcription modulators based on concordant hits from dual-reporter screening.
Cross-validating antiviral compound effects using complementary HepaRG and HepG2 cell models.
High-throughput screening of compound libraries for cccDNA-directed interventions.
Analyzing the relationship between secreted luminescent readouts and cccDNA-driven viral expression.
Strengths
Screens a substantial library of 1,403 FDA-approved compounds.
Employs a dual-reporter strategy for cross-validation, increasing result confidence.
Data is openly shared under a CC-BY-4.0 license, facilitating reuse.
Limitations
Column names and the exact row count are not provided, limiting understanding of the data structure.
The dataset's temporal and geographic scope for the underlying experiments is not specified.
Provenance
Source
Author: jiali cao
Collection Method
Data generated from high-throughput screening of compounds using two engineered hepatocyte reporter cell lines.